Carocell Bio · London & Charleston
Exploring peptide approaches to skin inflammation
Carocell Bio is developing peptide-based candidates with nanoparticle delivery for topical applications. Its research focuses on inflammatory skin conditions, led by an atopic dermatitis programme.
Preclinical & ex vivo research
Conceptual visualization — not a molecular structure, pathway diagram or experimental data.
The approach
Three ideas, one research platform
The company describes an approach that combines a molecular target inside the cell, a family of peptide candidates and a delivery strategy designed for the skin.
- 01
Peptide candidates
A portfolio of peptide-based anti-inflammatory molecules, each with its own identifier, indication and evidence level.
- 02
p38α MAPK signalling
The peptides are described as inhibitors of p38 alpha MAP kinase, an intracellular step in the inflammation cascade.
- 03
Topical nanoparticle delivery
Formulations combine the peptides with nanoparticle delivery for topical use, including a cream described for JEL0305.
Interactive 360° module
From peptide to evidence, in four stages
Rotate the conceptual object and step through the company’s scientific story. Every stage is also available as text below the scene.
Stage 1 of 4
Platform descriptionPeptide-based anti-inflammatory platform
Carocell Bio describes a portfolio of peptide-based anti-inflammatory molecules. The chain shown here is an abstract form: it does not represent any real sequence or structure.
›Text version of the four stages
01 · Platform description
Peptide-based anti-inflammatory platform
Carocell Bio describes a portfolio of peptide-based anti-inflammatory molecules. The chain shown here is an abstract form: it does not represent any real sequence or structure.
02 · Mechanism as described by the company
p38α MAPK — intracellular inflammation signalling
The candidates are described as peptide inhibitors of p38 alpha MAP kinase, a signalling step inside cells that the company associates with the production of inflammatory cytokines such as TNF-α, IL-1β and IL-6.
03 · Formulation concept
Topical nanoparticle delivery
The peptides are combined with nanoparticle delivery for topical application to the skin. The layered planes are a spatial metaphor for skin layers; no penetration or delivery data is depicted.
04 · Preclinical / ex vivo
Dermatitis: preclinical & ex vivo evidence
For JEL0305, the company reports cellular assays and studies on human skin biopsies (ex vivo). These are preclinical findings: they do not demonstrate efficacy or safety in patients.
Evidence, in context
What has been reported — and what has not
Company-reported
- Cellular assays measuring inflammatory cytokines
- Human ex vivo skin biopsy studies with histological comparisons
- 2022 ethics permission (HRA/HCRW/REC) for research on donated human tissue
Not established by reviewed sources
- Efficacy or safety in patients
- Prevention of recurrence in patients
- Any clinical phase or marketing approval
Lead programme
JEL0305 and atopic dermatitis
The company has reported results from cellular assays and human tissue biopsies. This work supports further development of the programme; patient efficacy, long-term recurrence prevention and clinical safety require clinical evidence.
Leadership
The people currently presented by the company
Dr Mike Davies
CEO & Founder
Anuj Madhok
CFO/CBO
Professor Anne Dickinson
Scientific and Clinical Advisor
Professor Yvonne Perrie
Scientific and Clinical Advisor
Latest announcements
From the news archive
The most recent post in the official archive is dated 22 December 2024.
2024 has been a busy and exciting year for Carocell Bio
Annual update reporting dermatitis biopsy work, a formulation collaboration, exploratory JEL3108 work on lung cancer cells and the portfolio grouping.
Carocell Bio Announced as Winner in Inaugural ‘Boston Bootcamp’ Competition
The company reports its selection among four winners of the inaugural Boston Bootcamp. The article’s header and body dates differ.
Carocell Bio’s CEO Presents at BioSeed 2024
The CEO presents the company at BioSeed 2024.
Research and partnering enquiries
Reach the company directly by email or telephone. This proposal does not collect or send messages.